Clinical Trials Browser

Phase 1 × INDUSTRY × fisogatinib × Clear all

NCT02508467 2024-04-12

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms